Mesa Laboratories (NASDAQ:MLAB) Sets New 1-Year High – What’s Next?

Mesa Laboratories, Inc. (NASDAQ:MLAB)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $155.12 and last traded at $154.76, with a volume of 80352 shares. The stock had previously closed at $147.79.

Analyst Ratings Changes

Separately, StockNews.com downgraded Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th.

Mesa Laboratories Price Performance

The company has a quick ratio of 0.51, a current ratio of 0.71 and a debt-to-equity ratio of 0.61. The firm has a fifty day moving average price of $136.30 and a 200 day moving average price of $126.97.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. On average, sell-side analysts forecast that Mesa Laboratories, Inc. will post 7.39 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Friday, February 28th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, February 28th. Mesa Laboratories’s dividend payout ratio (DPR) is presently -1.38%.

Hedge Funds Weigh In On Mesa Laboratories

A number of large investors have recently made changes to their positions in MLAB. FMR LLC raised its stake in Mesa Laboratories by 34.1% in the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 100 shares in the last quarter. Quantbot Technologies LP bought a new position in Mesa Laboratories in the 3rd quarter valued at approximately $70,000. Amundi boosted its position in Mesa Laboratories by 81.6% during the 4th quarter. Amundi now owns 661 shares of the medical instruments supplier’s stock worth $91,000 after buying an additional 297 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Mesa Laboratories during the 4th quarter worth approximately $132,000. Finally, Sanctuary Advisors LLC acquired a new position in Mesa Laboratories in the 2nd quarter valued at approximately $183,000. Institutional investors own 90.60% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.